The evaluation of iron status in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 7, Issue 12, 1996, Pages 2654-2657

  Fishbane, Steven ^a,b,c   Kowalski, Edward A ^a,b   Imbriano, Louis J ^a,b   Maesaka, John K ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Anemia; Erythropoietin; Ferritin; Iron deficiency; Transferrin saturation

Indexed keywords

FERRITIN; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; LABORATORY TEST; MALE; PRIORITY JOURNAL;

EID: 0030378023     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35: 712-716.
2. Fairbanks VF, Beutler E. Iron Deficiency. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Eds. Williams Hematology. New York: McGraw-Hill Inc.; 1995:490-509.
3. Macdougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 1994;3:620-625.
4. Besareb A, Ross RP, Nasca TJ: The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 1995;4:155-161.
5. Horl WH, Cavill I, Cove-Smith R, et al.: How to get the best out of r-HuEPO therapy? Nephrol Dial Transplant 1995;10:92-95.
6. Lipshitz DA, Cook JD, Finch CA: A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974;290:1213-1216.
7. Lynn KL, Mitchell TR, Shepperd J: Red cell indices and iron stores in patients undergoing hemodialysis. Br Med J 1981;282:2096.
8. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-163.
9. Horl WH, Cavill I, MacDougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during rHuEPO therapy: A consensus report. Nephrol Dial Transplant 1996;11:246-250.
10. Fishbane S, Lynn RI: The utility of zinc protoporphyrin in the diagnosis of iron deficiency in hemodialysis patients. Am J Kidney Dis 1995;25:426-432.
11. Kooistra MP van Es A, Struyvenberg A, Marx JJM: Low iron absorption in erythropoietin-treated hemodialysis patients [Abstract]. J Am Soc Nephrol 1995;6:543A.
12. Van Wyck DB: Iron deficiency in patients with dialysis associated anemia during erythropoietin replacement therapy: Strategies for assessment and management. Semin Nephrol 1995;9[Suppl 2]:21-24.
13. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995;44:238-240.
14. Fishbane S, Frei GL, Maesaka J: Reduction in rHuEPO doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
15. Valanis B. Epidemiology in Nursing and Health Care. Norwalk, CT: Appleton & Lange; 1992:333-340.
16. Baldus M, Salopek S, Moller M, et al.: Experiences with zinc protoporphyrin as a marker of endogenous iron availability in chronic hemodialysis patients. Nephrol Dial Transplant, in press.